Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 1
1982 1
1984 1
1985 1
1986 2
1987 5
1988 2
1989 3
1990 5
1991 2
1992 5
1993 1
1994 5
1995 7
1996 4
1997 6
1998 6
1999 8
2000 6
2001 12
2002 9
2003 10
2004 10
2005 6
2006 3
2007 4
2008 4
2009 11
2010 5
2011 2
2012 5
2013 8
2014 6
2015 10
2016 3
2017 10
2018 6
2019 5
2020 4
2021 5
2022 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Results by year

Filters applied: . Clear all
Page 1
Targeting FcRn to Generate Antibody-Based Therapeutics.
Ward ES, Ober RJ. Ward ES, et al. Trends Pharmacol Sci. 2018 Oct;39(10):892-904. doi: 10.1016/ Epub 2018 Aug 22. Trends Pharmacol Sci. 2018. PMID: 30143244 Free PMC article. Review.
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.
Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, Vankerckhoven B, Verheesen P, Ongenae N, Lykhopiy V, Enriquez FJ, Cho J, Ober RJ, Ward ES, de Haard H, Leupin N. Ulrichts P, et al. Among authors: ward es. J Clin Invest. 2018 Oct 1;128(10):4372-4386. doi: 10.1172/JCI97911. Epub 2018 Jul 24. J Clin Invest. 2018. PMID: 30040076 Free PMC article. Clinical Trial.
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group. Howard JF Jr, et al. Among authors: ward es. Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22. Neurology. 2019. PMID: 31118245 Free PMC article. Clinical Trial.
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.
Newland AC, Sánchez-González B, Rejtő L, Egyed M, Romanyuk N, Godar M, Verschueren K, Gandini D, Ulrichts P, Beauchamp J, Dreier T, Ward ES, Michel M, Liebman HA, de Haard H, Leupin N, Kuter DJ. Newland AC, et al. Among authors: ward es. Am J Hematol. 2020 Feb;95(2):178-187. doi: 10.1002/ajh.25680. Epub 2019 Dec 10. Am J Hematol. 2020. PMID: 31821591 Free PMC article. Clinical Trial.
Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial.
Goebeler M, Bata-Csörgő Z, De Simone C, Didona B, Remenyik E, Reznichenko N, Stoevesandt J, Ward ES, Parys W, de Haard H, Dupuy P, Verheesen P, Schmidt E, Joly P; ARGX-113-1701 Investigator Study Group. Goebeler M, et al. Among authors: ward es. Br J Dermatol. 2022 Mar;186(3):429-439. doi: 10.1111/bjd.20782. Epub 2021 Nov 28. Br J Dermatol. 2022. PMID: 34608631 Clinical Trial.
Targeting FcRn for the modulation of antibody dynamics.
Ward ES, Devanaboyina SC, Ober RJ. Ward ES, et al. Mol Immunol. 2015 Oct;67(2 Pt A):131-41. doi: 10.1016/j.molimm.2015.02.007. Epub 2015 Mar 9. Mol Immunol. 2015. PMID: 25766596 Free PMC article. Review.
206 results